A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK -RDOTAP/HPV-16 E6 & E7 Peptides) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent

Grants and Contracts Details

StatusActive
Effective start/end date11/2/207/26/25

Funding

  • PDS Biotechnology: $159,884.00